Linear Epitopes of Anthrax Toxin Protective Antigen for Development of a Peptide Vaccine
Posted Aug 22 2013 8:00pm
Description of Invention: Bacillus anthracis is a gram-positive, spore-forming bacteria that causes anthrax infection in humans. CDC inventors have identified epitope sequences of B. anthracis protective antigen (PA) that may be useful for development of peptide-based anthrax vaccines. This invention also relates to methods for determining whether post-vaccination protection is achieved. Specifically, this invention relates to a screening method for determining protection against B. anthracis infection that involves testing a biological sample for the presence of antibodies to one or more predefined regions of B. anthracis PA. This technology may be important to any bioterrorism defense strategy.
Novel anthrax vaccines
Post-vaccination screening to determine if anthrax protection is achieved
May require fewer vaccination follow-ups, while present anthrax vaccines require numerous rounds of injections and boosters for full-effectiveness.
Identified peptide sequences, representing regions of PA, elicit an immune response in primate and human sera studies.
In vitro data available
Inventors: Vera A Semenova (CDC) Conrad P Quinn (CDC) Jan Pohl (CDC) Pavel Svoboda (CDC)
For Licensing Information Please Contact: Whitney Blair NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: firstname.lastname@example.org Phone: 301-435-4937 Fax: 301-402-0220